Skip to content

Bryan L. Roth

National Institute of Mental Health, University of North Carolina at Chapel Hill

48 papers in the library · 5,431 citations · publishing 2001-2026

Papers

Sort Most recent Most cited

No evidence for direct physical interaction of 5-HT 2A -mGluR2 receptors in vitro or in vivo

bioRxiv (Cold Spring Harbor Laboratory) June 30, 2026 Blake A Fordyce, Yi-Ting Chiu, Nicholas A. Wright et al.

Abstract Activation of mGluR2 (metabotropic glutamate receptor 2), the primary presynaptic autoreceptor for glutamate in the brain, is well established to attenuate the psychedelics-mediated behavioral and electrophysiological effects. However, the mechanisms responsible for these actions are controversial. The two competing mechanistic hypotheses have been proposed to explain this phenomenon...

Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation

Translational Psychiatry October 6, 2025 Gavin P. Schmitz, Yi-Ting Chiu, Mia L. Foglesong et al. 13 citations

Psilocybin, and its active metabolite psilocin, have seen renewed interest due to studies suggesting potential therapeutic utility. 5-Hydroxytryptamine2A receptors (5-HT 2A Rs) are primary mediators of the psychoactive effects of psychedelics in animals and humans, but the underlying neurobiological mechanisms remain poorly understood. Functional magnetic resonance imaging identified...

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.

Neuron July 15, 2025 Manish K. Jain, Ryan H. Gumpper, Samuel T. Slocum et al. 42 citations

The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-HT2A serotonin receptor (5-HT2AR). Recent clinical studies have suggested that classical psychedelics may additionally have therapeutic potential for many neuropsychiatric conditions including depression, anxiety, migraine and cluster headaches, drug...

The structural diversity of psychedelic drug actions revealed.

Nat Commun March 19, 2025 Ryan H. Gumpper, Manish K. Jain, Kuglae Kim et al. 31 citations

There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT2A serotonin receptor. Here, we present 7 cryo-EM structures covering all major compound...

AlphaFold2 structures guide prospective ligand discovery

Science May 16, 2024 Jiankun Lyu, Nicholas J. Kapolka, Ryan H. Gumpper et al. 145 citations

AlphaFold2 (AF2) models have had wide impact but mixed success in retrospective ligand recognition. We prospectively docked large libraries against unrefined AF2 models of the σ 2 and serotonin 2A (5-HT2A) receptors, testing hundreds of new molecules and comparing results with those obtained from docking against the experimental structures. Hit rates were high and similar for the experimental...

Making Sense of Psychedelics in the CNS

The International Journal of Neuropsychopharmacology January 30, 2024 Blake A Fordyce, Bryan L. Roth 4 citations

Abstract For centuries, ancient lineages have consumed psychedelic compounds from natural sources. In the modern era, scientists have since harnessed the power of computational tools, cellular assays, and behavioral metrics to study how these compounds instigate changes on molecular, cellular, circuit-wide, and system levels. Here, we provide a brief history of psychedelics and their use in...

Psychedelics: preclinical insights provide directions for future research

Neuropsychopharmacology 2024 Ryan H. Gumpper, Bryan L. Roth

Recently, psychedelics have emerged as promising therapeutics for numerous neuropsychiatric disorders. While their potential in the clinic has yet to be fully elucidated, understanding their molecular and biological mechanisms is imperative as these compounds are becoming widely used both in therapeutic and recreational contexts. This review examines the current understanding of basic biology,...

A suite of engineered mice for interrogating psychedelic drug actions

bioRxiv (Cold Spring Harbor Laboratory) September 26, 2023 Yi-Ting Chiu, Wei Wang, Pierre Llorach et al. 15 citations preprint

ABSTRACT Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many neuropsychiatric diseases, including depression, anxiety, post-traumatic stress disorder, migraine, and cluster headaches. LSD and psilocybin exert their psychedelic effects via activation of the 5-hydroxytryptamine 2A receptor (HTR2A). Here we provide...

Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.

Cell May 11, 2023 Isha Singh, Anubha Seth, Christian B. Billesbølle et al. 97 citations

The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has unusual anti-depressant and substance-withdrawal effects, and stabilizes the inward-open conformation. Unfortunately, ibogaine's promiscuity...

Psychedelics as Transformative Therapeutics.

The American journal of psychiatry May 1, 2023 Bryan L. Roth, Ryan H. Gumpper 55 citations

Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions. However, historically most of the basic science has utilized these compounds as probes to interrogate various endogenous neurotransmitter systems-mainly the serotonin 5-HT2A receptor. With the renewed interest in utilizing these compounds...

The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice.

Frontiers in Molecular Biosciences 2023 Vladimir M Pogorelov, Ramona M. Rodriguiz, Bryan L. Roth et al. 26 citations

There is now evidence from multiple Phase II clinical trials that psychedelic drugs can exert long-lasting anxiolytic, anti-depressant, and anti-drug abuse (nicotine and ethanol) effects in patients. Despite these benefits, the hallucinogenic actions of these drugs at the serotonin 2A receptor (5-HT2AR) limit their clinical use in diverse settings. Activation of the 5-HT2AR can stimulate both G...

Psychedelic compounds directly excite 5-HT 2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT 2A Gq -mediated activation mechanism

bioRxiv (Cold Spring Harbor Laboratory) November 15, 2022 Gavin P. Schmitz, Yi-Ting Chiu, Gabriele M. König et al. 15 citations preprint

Summary Psilocin, the active compound in Psilocybe sp . mushrooms, is a serotonergic psychedelic that has recently gained renewed interest due to its potential as a therapeutic tool. Despite promising clinical findings, the underlying signaling mechanisms and brain region-specific effects of psilocin and other psychedelic drugs remain unclear. Psilocin, like other psychedelic compounds, is an...

The neural basis of psychedelic action.

Nat Neurosci October 24, 2022 Alex C. Kwan, David E. Olson, Katrin H. Preller et al. 291 citations

Psychedelics are serotonin 2A receptor agonists that can lead to profound changes in perception, cognition and mood. In this review, we focus on the basic neurobiology underlying the action of psychedelic drugs. We first discuss chemistry, highlighting the diversity of psychoactive molecules and the principles that govern their potency and pharmacokinetics. We describe the roles of serotonin...

Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.

Neuron October 5, 2022 Can Cao, Ximena Barros-Álvarez, Shicheng Zhang et al. 158 citations

Serotonin (5-hydroxytryptamine [5-HT]) 5-HT2-family receptors represent essential targets for lysergic acid diethylamide (LSD) and all other psychedelic drugs. Although the primary psychedelic drug effects are mediated by the 5-HT2A serotonin receptor (HTR2A), the 5-HT2B serotonin receptor (HTR2B) has been used as a model receptor to study the activation mechanisms of psychedelic drugs due to...

Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors

Cell Reports August 1, 2022 Ryan H. Gumpper, Jonathan F. Fay, Bryan L. Roth 49 citations

-transducer-coupled structures of three representative isoforms (INI, VGV, and VSV) with the selective drug lorcaserin (Belviq) and the classic psychedelic psilocin. We also provide a comprehensive analysis of agonist activation and constitutive activity across all 24 protein isoforms. Collectively, these findings reveal a unique hydrogen-bonding network located on intracellular loop 2 that is...

The promises and perils of psychedelic pharmacology for psychiatry.

Nature reviews. Drug discovery June 1, 2022 Tristan D Mcclure-Begley, Bryan L. Roth 195 citations

Psychedelic drugs including psilocybin, N,N'-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. Notably, phase II trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in...

Pharmacologic analysis of non-synonymous coding 5-HT2A SNPs reveals alterations psychedelic drug potencies and efficacies

bioRxiv Preprint Server December 9, 2021 Gavin P. Schmitz, Manish K. Jain, Samuel T. Slocum et al. preprint

Serotonin (5-Hydroxytryptamine; 5-HT) 2A receptor (5-HT2AR) signaling is essential for the actions of classical psychedelic drugs. In this study, we examined whether random sequence variations in the gene (single nucleotide polymorphisms, SNPs) encoding the 5-HT2AR affect the signaling of four commonly used psychedelic drugs. We examined the in vitro pharmacology of seven non-synonymous SNPs,...

Molecular insights into psychedelic drug action

Journal of Neurochemistry November 19, 2021 Samuel T. Slocum, Jeffrey F. Diberto, Bryan L. Roth 59 citations

Abstract A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the...

LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1

Scientific Reports September 5, 2021 Ramona M. Rodriguiz, Vineet Nadkarni, Christopher R. Means et al. 92 citations

Abstract Recent evidence suggests that psychedelic drugs can exert beneficial effects on anxiety, depression, and ethanol and nicotine abuse in humans. However, their hallucinogenic side-effects often preclude their clinical use. Lysergic acid diethylamide (LSD) is a prototypical hallucinogen and its psychedelic actions are exerted through the 5-HT2A serotonin receptor (5-HT2AR). 5-HT2AR...

LSD’s effects are differentially modulated in arrestin knockout mice

bioRxiv Preprint Server February 4, 2021 Ramona M. Rodriguiz, Vineet Nadkarni, Christopher R. Means et al. 7 citations preprint

Recent evidence suggests that psychedelic drugs can exert beneficial effects on anxiety, depression, and ethanol and nicotine abuse in humans. However, the hallucinogenic side-effects of psychedelics often preclude their clinical use. Lysergic acid diethylamide (LSD) is a prototypical hallucinogen and its psychedelic actions are exerted through the 5-HT2A serotonin receptor (5-HT2AR). 5-HT2AR...

trans -2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans -2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT 2 receptor family

UNC Libraries October 31, 2020 Adam Pigott, Bryan L. Roth, Xi-Ping Huang et al.

A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4-iodoamphetamine (DOI, 1a), and 2,5-dimethoxy-4-bromoamphetamine (DOB, 1b) with a cyclopropylamine moiety was successful in leading to compounds with high affinity at the 5-HT2 family of receptors; and the more potent stereoisomer of the cyclopropane analogues had the expected (−)-(1R,2S)-configuration. Screening for affinity at...

The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor.

PLoS One June 14, 2016 Bryan L. Roth, Simon Gibbons, Warunya Arunotayanun et al. 153 citations

In this paper we determined the pharmacological profiles of novel ketamine and phencyclidine analogues currently used as 'designer drugs' and compared them to the parent substances via the resources of the National Institute of Mental Health Psychoactive Drug Screening Program. The ketamine analogues methoxetamine ((RS)-2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone) and 3-MeO-PCE...

Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.

European journal of medicinal chemistry October 6, 2014 Prabhakar R Polepally, Krzysztof Huben, Eyal Vardy et al. 28 citations

The neoclerodane diterpenoid salvinorin A is a major secondary metabolite isolated from the psychoactive plant Salvia divinorum. Salvinorin A has been shown to have high affinity and selectivity for the κ-opioid receptor (KOR). To study the ligand-receptor interactions that occur between salvinorin A and the KOR, a new series of salvinorin A derivatives bearing potentially reactive Michael...

Chemotype-selective modes of action of κ-opioid receptor agonists.

The Journal of biological chemistry November 29, 2013 Eyal Vardy, Philip D Mosier, Kevin J Frankowski et al.

The crystal structures of opioid receptors provide a novel platform for inquiry into opioid receptor function. The molecular determinants for activation of the κ-opioid receptor (KOR) were studied using a combination of agonist docking, functional assays, and site-directed mutagenesis. Eighteen positions in the putative agonist binding site of KOR were selected and evaluated for their effects...

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.

Bioorganic & Medicinal Chemistry Letters June 1, 2013 Warunya Arunotayanun, Jeffrey W Dalley, Xi-Ping Huang et al. 41 citations

Novel Psychoactive Drugs (NPD) can be sold without restriction and are often synthetic analogues of controlled drugs. The tryptamines are an important class of NPD as they bind to the various serotonin (5-HT) receptor subtypes and cause psychosis and hallucinations that can lead to injury or death through misadventure. Here we report on the structure elucidation and receptor binding profiles of...